Credit Suisse AG grew its holdings in Geron Corporation (NASDAQ:GERN) by 51.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 235,969 shares of the biopharmaceutical company’s stock after acquiring an additional 80,432 shares during the period. Credit Suisse AG owned about 0.15% of Geron Corporation worth $535,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its holdings in Geron Corporation by 7.6% during the 1st quarter. Vanguard Group Inc. now owns 7,112,183 shares of the biopharmaceutical company’s stock valued at $16,145,000 after purchasing an additional 502,485 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Geron Corporation during the 1st quarter worth $820,000. Geode Capital Management LLC grew its holdings in Geron Corporation by 11.0% during the 1st quarter. Geode Capital Management LLC now owns 1,212,214 shares of the biopharmaceutical company’s stock worth $2,751,000 after acquiring an additional 120,222 shares in the last quarter. KCG Holdings Inc. grew its holdings in Geron Corporation by 132.5% during the 1st quarter. KCG Holdings Inc. now owns 167,755 shares of the biopharmaceutical company’s stock worth $381,000 after acquiring an additional 95,615 shares in the last quarter. Finally, UBS Asset Management Americas Inc. grew its holdings in Geron Corporation by 91.9% during the 1st quarter. UBS Asset Management Americas Inc. now owns 105,125 shares of the biopharmaceutical company’s stock worth $239,000 after acquiring an additional 50,334 shares in the last quarter. 38.79% of the stock is currently owned by institutional investors and hedge funds.
Several research analysts have weighed in on the stock. FBR & Co reissued a “buy” rating on shares of Geron Corporation in a report on Tuesday, July 4th. BidaskClub lowered shares of Geron Corporation from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Finally, Zacks Investment Research lowered shares of Geron Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, June 14th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. Geron Corporation currently has a consensus rating of “Hold” and a consensus price target of $3.88.
TRADEMARK VIOLATION WARNING: “Credit Suisse AG Boosts Stake in Geron Corporation (NASDAQ:GERN)” was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/credit-suisse-ag-purchases-80432-shares-of-geron-corporation-gern/1563324.html.
Geron Corporation (GERN) opened at 2.15 on Friday. The stock has a 50 day moving average of $2.17 and a 200 day moving average of $2.47. The firm’s market capitalization is $343.10 million. Geron Corporation has a 12-month low of $1.81 and a 12-month high of $3.15.
Geron Corporation (NASDAQ:GERN) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. Geron Corporation had a negative return on equity of 21.30% and a negative net margin of 433.72%. The business had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.38 million. During the same quarter last year, the firm posted ($0.05) EPS. The company’s quarterly revenue was down 19.0% on a year-over-year basis. Equities research analysts anticipate that Geron Corporation will post ($0.18) earnings per share for the current year.
Geron Corporation Company Profile
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.
Receive News & Ratings for Geron Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Corporation and related companies with our FREE daily email newsletter.